W. Ai

发表

Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.

R. Advani, P. Bierman, L. Gordon, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

A Case of EBV-Negative Aggressive NK-cell Leukemia: Use of Next-Generation Sequencing in Demystifying a Diagnostic Dilemma and Guiding Clinical Care.

Diwash Jangam, R. Ruiz-Cordero, W. Ai, 2021, Clinical lymphoma, myeloma & leukemia.

Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission

A. Logan, K. Gaensler, Catherine C. Smith, 2016, Leukemia & lymphoma.

Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

R. Houot, J. Briones, C. Flowers, 2021, Leukemia & lymphoma.

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.

W. Choi, J. Winter, M. Piris, 2013, Blood.

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.

R. Tibshirani, R. Levy, R. Advani, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

R. Advani, P. Bierman, L. Gordon, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Hodgkin Lymphoma, Version 2.2020

R. Advani, P. Bierman, L. Gordon, 2020 .

S. Kambhampati, C. Andreadis, W. Ai, 2019, Clinical lymphoma, myeloma & leukemia.

Hodgkin lymphoma, version 2.2015.

R. Advani, P. Bierman, L. Gordon, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.

P. Bierman, I. Flinn, C. Flowers, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases.

D. Arber, O. Weinberg, W. Ai, 2007, The Journal of molecular diagnostics : JMD.

Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T‐regulatory cells

R. Negrin, W. Ai, R. Zeiser, 2009, International journal of cancer.

NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.

M. Dwyer, A. Goodman, S. Ansell, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.

M. Dwyer, S. Ansell, Hema M Sundar, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Title Outcomes after diagnosis of mycosis fungoides and Sézary syndrome before 30 years of age : A population-based study

Youn H. Kim, T. Keegan, W. Ai, 2014 .

Outcomes after diagnosis of mycosis fungoides and Sézary syndrome before 30 years of age: a population-based study.

E. Chang, Youn H. Kim, T. Keegan, 2014, JAMA dermatology.

Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma

A. Stathis, S. Liao, J. Boni, 2021, The AAPS Journal.

The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy

K. Ardeshna, M. Lunning, P. Caimi, 2021, Clinical Lymphoma Myeloma and Leukemia.

Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study

F. McCormick, P. Porcu, C. Andreadis, 2019, Clinical Cancer Research.

T-Cell Lymphomas, Version 2.2022

M. Dwyer, A. Goodman, S. Ansell, 2022 .

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma.

R. Tibshirani, D. Czerwinski, W. Ai, 2007, Blood.

Peripheral T-Cell Lymphoma, Not Otherwise Specified Presenting as Erythroderma

P. Leboit, W. Ai, L. Pincus, 2014 .

Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909

R. Advani, D. Czerwinski, S. Horning, 2008 .

Successful idiotypic vaccination following stem cell allotransplant in lymphoma

E. Soria, W. Ai, S. Inogés, 2013, Leukemia & lymphoma.

NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.

M. Dwyer, A. Goodman, S. Ansell, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Hodgkin lymphoma.

R. Advani, P. Bierman, L. Gordon, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

R. Advani, P. Bierman, L. Gordon, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic

O. Akilov, M. Shinohara, J. Zic, 2020, Journal of the American Academy of Dermatology.

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.

W. Choi, J. Winter, M. Piris, 2012, Blood.

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

K. Dybkær, G. Bhagat, Y. Zu, 2014, Leukemia.

Use of an expanded immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators

R. Cho, T. McCalmont, W. Ai, 2012, Journal of cutaneous pathology.

LOTIS 2 FOLLOW-UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

J. Radford, P. Zinzani, K. Ardeshna, 2021 .

Acneiform presentation of primary cutaneous follicle center lymphoma.

T. McCalmont, W. Ai, L. Pincus, 2011, Journal of the American Academy of Dermatology.

Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.

Michael L. Wang, W. Choi, J. Winter, 2013, Blood.

Plenary Paper

W. Choi, R. Gascoyne, G. Slack, 2013 .

B-cell lymphoma patients treated with R-CHOP : report from an Mutational profile and prognostic significance of TP 53 in diffuse large

W. Choi, J. Winter, K. Dybkær, 2012 .

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study

W. Choi, J. Winter, K. Dybkær, 2013, Haematologica.

K. Dybkær, W. Tam, G. Bhagat, 2012, Leukemia.

Cutaneous T cell lymphoma PDX drug screening platform identifies cooperation between inhibitions of PI3Kα/δ and HDAC.

Sourav Bandyopadhyay, M. Moasser, F. McCormick, 2020, The Journal of investigative dermatology.

C-C chemokine receptor 1 expression in human hematolymphoid neoplasia.

Matthew W. Anderson, R. Tibshirani, I. Lossos, 2010, American journal of clinical pathology.

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.

W. Choi, J. Winter, K. Dybkær, 2013, Blood.

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Peggy Wu, M. Dwyer, A. Goodman, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Current and emerging treatment options in primary mediastinal B-cell lymphoma

W. Ai, B. Fakhri, 2021, Therapeutic advances in hematology.

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018

R. Advani, P. Bierman, L. Gordon, 2018 .

Management of advanced stage Hodgkin lymphoma.

R. Advani, S. Horning, W. Ai, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.

J. Radford, P. Zinzani, K. Ardeshna, 2021, The Lancet. Oncology.

Racial patterns of extranodal natural killer/T‐cell lymphoma, nasal type, in California: a population‐based study

D. Weisenburger, K. Fu, E. Chang, 2012, British journal of haematology.

Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries

W. Choi, J. Winter, M. Piris, 2014, Clinical Cancer Research.

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.

W. Choi, R. Gascoyne, G. Slack, 2013, Blood.

Rituximab-CHOP Consortium Program demonstrates high-risk gene expression signatures : a report from The activated B-cell subtype of diffuse large B-cell lymphoma and MYC / BCL 2 protein coexpression contributes to the inferior survival of

W. Choi, R. Gascoyne, G. Slack, 2013 .

Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation.

Chiung-Yu Huang, A. Logan, C. Andreadis, 2020, Journal of geriatric oncology.

Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC.

L. Schwartz, J. Scarisbrick, E. Guenova, 2021, Blood.

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

J. Radford, P. Zinzani, K. Ardeshna, 2020 .

Prolonged disease‐free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma

H. Kohrt, J. Timmerman, W. Ai, 2011, American journal of hematology.

Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.

K. Gaensler, Catherine C. Smith, C. Andreadis, 2014, Journal of geriatric oncology.

Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.

A. Logan, M. Faham, K. Kong, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.

R. Tibshirani, R. Advani, D. Czerwinski, 2012, Blood.

Association of a Proposed New Staging System for Folliculotropic Mycosis Fungoides With Prognostic Variables in a US Cohort.

J. Kornak, M. Kashani-Sabet, P. Leboit, 2020, JAMA dermatology.

Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.

Chiung-Yu Huang, S. Kambhampati, C. Andreadis, 2020, Clinical lymphoma, myeloma & leukemia.

Update on the Treatment of Anaplastic Large Cell Lymphoma

W. Ai, Khoan Vu, Weiyun Ai, 2018, Current Hematologic Malignancy Reports.

Low incidence of Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly in Tianjin, northern China

K. Fu, Baocun Sun, X. Hao, 2013, Leukemia & lymphoma.

Mutational Profile and Prognostic Significance of TP53 in Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-CHOP: A Report From an International DLBCL Rituximab-CHOP Consortium Program Study

W. Choi, J. Winter, K. Dybkær, 2013 .

The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study

W. Choi, J. Winter, K. Dybkær, 2011 .

Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program

J. Winter, K. Dybkær, M. Piris, 2013 .

Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.

S. Kambhampati, J. Tuscano, C. Andreadis, 2020, Clinical lymphoma, myeloma & leukemia.

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

J. Radford, K. Ardeshna, A. Stathis, 2022, Blood advances.

A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies.

I. Flinn, A. Wiestner, S. O'brien, 2022, Journal of Clinical Oncology.

Hodgkin Lymphoma Version 1 . 2017 Clinical Practice Guidelines in Oncology

R. Advani, P. Bierman, L. Gordon, 2017 .

Left ventricular rupture due to HIV-associated T-cell lymphoma.

E. Armstrong, P. Ursell, Y. Yeghiazarians, 2010, Texas Heart Institute Journal.

NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.

R. Advani, L. Gordon, M. Kaminski, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab

R. Houot, J. Briones, C. Flowers, 2017 .

Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models

M. Moasser, F. McCormick, R. Gill, 2021, Blood advances.

ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

J. Radford, P. Zinzani, K. Ardeshna, 2021 .

High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomas

T. Link, M. Steinman, C. Andreadis, 2021, Supportive Care in Cancer.

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

I. Flinn, O. Abdel-Wahab, A. Wiestner, 2022, Blood.

Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis

T. Naoe, A. Logan, A. Leavitt, 2015, Bone Marrow Transplantation.

In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study

R. Tibshirani, Y. Natkunam, R. Advani, 2010 .

Hypoxia-specific imaging in patients with lymphoma undergoing CAR-T therapy.

V. Wang, Chiung-Yu Huang, C. Andreadis, 2023, European journal of nuclear medicine and molecular imaging.

A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.

L. Benet, A. Logan, K. Gaensler, 2015, Clinical lymphoma, myeloma & leukemia.

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.

Chad A. LaGrange, Geoffrey E. Wile, R. Advani, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.

Chiung-Yu Huang, A. Logan, C. Andreadis, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic

O. Akilov, M. Shinohara, J. Zic, 2020, Journal of the American Academy of Dermatology.

Prognostic Relevance of Dominant Blood T-Cell Clones in Early Mycosis Fungoides-Reply.

W. Ai, L. Pincus, Y. Charli-Joseph, 2022, JAMA dermatology.

Association of a Dominant T-Cell Clone in Peripheral Blood With Time to Systemic Treatment in Patients With Stage IB Mycosis Fungoides.

Chiung-Yu Huang, W. Ai, L. Pincus, 2022, JAMA dermatology.

Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin

C. Andreadis, W. Ai, B. Fakhri, 2021, Leukemia & lymphoma.

Plenary Paper

W. Choi, R. Gascoyne, G. Slack, 2013 .

Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study

W. Ai, T. Feldman, M. Lechowicz, 2023, Haematologica.